University of Edinburgh
Mechanisms of presynaptic loss of function in Huntington's disease
Abstract
dc:description.abstractHuntington’s Disease (HD) is a rare, inherited neurodegenerative disorder caused by polymorphic expansion mutations of the CAG repeat in the HTT gene. The HTT gene encodes huntingtin (Htt), a large multifunctional protein. The CAG repeat expansion results in the production of mutant huntingtin (mHtt), containing a correspondingly elongated polyglutamine tract. Ultimately, mutation of HTT markedly disrupts multiple cellular functions and initiates widespread neuronal dysfunction, leading to progressive neurodegeneration. Medium spiny neurons (MSNs) of the striatum are particularly vulnerable to neurodegeneration in HD, though, as the disease progresses, neuronal death becomes widespread, giving rise to characteristic motor, cognitive, and psychiatric impairments. Despite advances in understanding the disease mechanisms, there are currently no licensed therapies capable of reversing or halting HD progression, and the precise physiological role of Htt remains elusive. Early disturbances in synaptic physiology are increasingly recognised as a common feature in the pathogenesis of neurodegenerative diseases and may initiate pathological cascades that precipitate eventual neurodegeneration. One such facet of synaptic physiology is synaptic vesicle (SV) endocytosis, an essential process by which SVs are reformed, and vesicle pools are replenished following SV exocytosis. The dominant mode of SV retrieval during periods of intense neuronal stimulation is activity-dependent bulk endocytosis (ADBE). Previous research in this lab has identified a striking increase in the number of nerve terminals that perform ADBE in primary neurons derived from CAG Q140 knock-in HD model mice compared to wild-type (WT) controls. This early defect in SV endocytosis points towards presymptomatic synaptic dysfunction as a driver of disease pathogenesis in HD. This thesis investigates the molecular underpinnings of aberrant ADBE observed in HD and the role of Htt in ADBE regulation by exploring whether increased ADBE recruitment stems from the loss of normal Htt function or is due to a toxic gain-of-function conferred by mHtt. By using a tetramethylrhodamine-dextran uptake assay to monitor ADBE, it was observed that overexpression of WT Htt protein is suVicient to restore normal levels of ADBE recruitment in HD neurons, whilst selective depletion of mHtt failed to do so. These findings suggest that Htt haploinsuViciency, not simply the presence of mHtt, drives increased recruitment of ADBE in HD. Further experiments identified that the N-terminal region of Htt is dispensable for restoring proper ADBE recruitment, as overexpression of Htt lacking the N-terminus is suVicient to rescue normal ADBE recruitment, whereas the N-terminal of Htt alone does not. Surprisingly, expression of mHtt was also found to rescue normal ADBE recruitment, suggesting that the role of Htt in ADBE recruitment is not strictly dependent on its mutation status, at least in this experimental context. Subsequently, to expand the mechanistic knowledge of Htt function in ADBE, mass spectrometry data of endosome purifications and Htt synaptosome immunoprecipitations from both WT and CAG Q140 knock-in mice were analysed. This identified several candidate modifiers of the endocytic HD phenotype, including Huntingtin-interacting protein 14 (HIP14) and Huntingtinassociated protein 40 (HAP40). Accordingly, these proteins were manipulated in vitro to determine their viability as targets for rescuing increased ADBE in HD. Notably, depletion of HIP14, which normally palmitoylates Htt, and expression of palmitoylation-resistant Htt both restored normal ADBE recruitment in HD neurons, suggesting that Htt palmitoylation is not essential for ADBE and that targeting palmitoylation pathways may reflect a novel therapeutic avenue for HD treatment. Conversely, overexpression but not depletion of HAP40, an interactor that stabilises Htt, rescued excess ADBE recruitment in HD neurons, implicating Htt stability as a critical factor in the role of Htt in ADBE. Lastly, the role of adaptor-related protein complex 3 subunit Beta 2 (AP3B2), another candidate modifier of ADBE identified here, was investigated in the context of both HD and epilepsy, given that mutations of AP3B2 are known to cause early-onset epileptic encephalopathy. Strikingly, depletion of AP3B2 from WT neurons replicated the increased ADBE recruitment seen in HD neurons, which could be reversed by co-expression with shRNA-resistant WT AP3B2 but not by patient-derived G909S mutant AP3B2. Interestingly, manipulation of AP3B2 levels in HD neurons did not affect ADBE recruitment, suggesting that AP3B2 function is already impaired in HD and may therefore be involved in the mechanism that causes increased ADBE recruitment in HD. In summary, these results advance our understanding of the mechanism underlying early synaptic dysfunction in Huntington’s disease, highlighting Htt loss of function and altered protein interactions as key drivers of pathogenic ADBE recruitment. The identification of modifiable molecular targets within this pathway highlights new avenues for potential therapeutic intervention before overt neurodegeneration. Furthermore, analysis of a candidate modifier linked to epilepsy suggests that aberrant ADBE recruitment may reflect a convergent phenotype of multiple neurological disorders, though potentially via distinct molecular mechanisms.
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Tan, Han
- Advisors dc:contributor.advisor
-
- Smillie, Karen
- Cousin, Michael
- Jackson, Mandy
Subjects
dc:subject × 10Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Identifier URI
- https://doi.org/10.7488/era/7324